ArticleNeuropsychopharmacology reports2026
High Adherence to Pharmacological Treatment Guidelines in Recovery and Remission States Among Patients With Schizophrenia: A Cross-Sectional Study.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSeveral schizophrenia guidelines have been published, showing treatment efficacy. However, no studies have examined recovery and pharmacological therapy or guideline adherence's impact on various schizophrenia states. This study aimed to investigate adherence to pharmacological guidelines across recovery, remission, and non-remission states in patients with schizophrenia.
methodsThis cross-sectional study included 72 patients with schizophrenia who met the criteria for recovery, remission, or non-remission. Adherence to pharmacological guidelines was measured using the Individual Fitness Score (IFS).
resultsIFS was significantly higher in the recovery (88.1 ± 18.9) and remission (89.0 ± 16.7) groups than in the non-remission group (65.59 ± 21.8) (p < 0.01). However, no significant differences were observed between the recovery and remission groups. Receiver operating characteristic analysis identified 72 points on the IFS as a potential cutoff point between remission and non-remission.
conclusionThese results show that higher adherence to pharmacological guidelines may be associated with recovery and remission state, compared with non-remission state. The cutoff point between remission and non-remission should be considered preliminary and exploratory because of a small sample. Clinical practice guidelines have been developed to standardize and improve the quality of medical care. Treatments following these guidelines have been reported to be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.